North West Centre of Advanced Drug Delivery (NoWCADD), Division of Pharmacy & Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, Stopford Building, Manchester, M13 9PT, United Kingdom.
Pharmaceutical Technology & Development, AstraZeneca, Macclesfield, SK10 2NA, United Kingdom.
Int J Pharm. 2017 Dec 20;534(1-2):97-107. doi: 10.1016/j.ijpharm.2017.10.006. Epub 2017 Oct 7.
We have employed microfluidics (cross-shaped chip) for the preparation of drug-loaded poly(lactic acid-co-glycolic acid) (PLGA) nanoparticles. The polymer precipitates from an acetone solution upon its controlled laminar mixing (flow focusing) with an aqueous solution of a surfactant, allowing for an operator-independent, up-scalable and reproducible preparative process of nanoformulations. Firstly, using PEGylated surfactants we have compared batch and microfluidic processes, and showed the superior reproducibility of the latter and its strong dependency on the acetone/water ratio (flow rate ratio). We have then focused on the issue of purification from free surfactant, and employed advanced characterization techniques such as flow-through dynamic light scattering as the in-line quality control technique, and field flow fractionation (FFF) with dynamic and static light scattering detection, which allowed the detection of surfactant micelles in mixture with nanoparticles (hardly possible with stand-alone dynamic light scattering). Finally, we have shown that the choice of polymer and surfactant affects the release behaviour of a model drug (paclitaxel), with high molecular weight PLGA (RG756) and low molecular weight surfactant (tocopheryl poly(ethylene glycol) 1000 succinate, TPGS) apparently showing higher burst and accelerated release.
我们采用微流控(十字形芯片)来制备载药聚乳酸-共-羟基乙酸(PLGA)纳米粒。聚合物在丙酮溶液中沉淀,通过与含有表面活性剂的水溶液的可控层流混合(流动聚焦)来实现,从而实现了一种操作员独立、可扩展和可重复的纳米制剂制备过程。首先,我们使用聚乙二醇化表面活性剂比较了批量和微流控工艺,结果表明后者具有更好的重现性,且强烈依赖于丙酮/水的比例(流速比)。然后,我们专注于从游离表面活性剂中进行纯化的问题,并采用先进的表征技术,如在线流通动态光散射作为质量控制技术,以及场流分级(FFF)与动态和静态光散射检测,这使得可以检测到与纳米粒混合的表面活性剂胶束(用独立的动态光散射几乎不可能检测到)。最后,我们表明,聚合物和表面活性剂的选择会影响模型药物(紫杉醇)的释放行为,高分子量 PLGA(RG756)和低分子量表面活性剂(生育酚聚乙二醇 1000 琥珀酸酯,TPGS)显然表现出更高的突释和加速释放。